Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Judson

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsAnne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trialSandro Pasquali, Sara Pizzamiglio, Nathan Touati, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomasGeorgios Kantidakis, Saskia Litière, Anouk Neven, et al.
Journal of Adolescent and Young Adult Oncology|May 8, 2020
Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center ExperienceEugenie Younger, Olga Husson, Bernice Asare, et al.
European Radiology|June 24, 2009
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trialDow-Mu Koh, Matthew Blackledge, David J Collins, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2022
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomasGeorgios Kantidakis, Saskia Litière, Anouk Neven, et al.
Sarcoma|December 27, 2013
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcomaJuan Martin-Liberal, Salma Alam, Anastasia Constantinidou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trialAxel Le Cesne, Martine Van Glabbeke, Jaap Verweij, et al.
Medical Oncology (Northwood, London, England)|August 22, 2018
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcomaAlexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsAnne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trialSandro Pasquali, Sara Pizzamiglio, Nathan Touati, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomasGeorgios Kantidakis, Saskia Litière, Anouk Neven, et al.
Journal of Adolescent and Young Adult Oncology|May 8, 2020
Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center ExperienceEugenie Younger, Olga Husson, Bernice Asare, et al.
European Radiology|June 24, 2009
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trialDow-Mu Koh, Matthew Blackledge, David J Collins, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2022
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomasGeorgios Kantidakis, Saskia Litière, Anouk Neven, et al.
Sarcoma|December 27, 2013
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcomaJuan Martin-Liberal, Salma Alam, Anastasia Constantinidou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupMichael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trialAxel Le Cesne, Martine Van Glabbeke, Jaap Verweij, et al.
Medical Oncology (Northwood, London, England)|August 22, 2018
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcomaAlexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, et al.
Pageof 16